


DIGNITANA

Clinically superior scalp cooling

NOVEMBER 18 • 2021

**Moving toward cash
flow positivity in 2022
with accelerating
reimbursement activity**



Q3 21

QUARTERLY REPORT

Moving toward cash flow positivity in 2022 with accelerating reimbursement activity

Financial highlights Q3 2021

- Net sales amounted to 13,7 MSEK (10.9), an increase of 25 percent over the same period 2020.
- Operating result amounted to -13.6 MSEK (-9,5)
- Net result after financial items amounted to -13.9 MSEK (-9.9)
- Earnings per share were -0,21 SEK (-0,18)
- Cash Balance amounted to 21.0 MSEK (14.8)
- Average Daily Treatment Revenue (ADTR)* was 147 TSEK (99), an increase of 47 percent over the same period in 2020.

Financial highlights

January – September 2021

- Net sales amounted to 40.9 MSEK (33.7), an increase of 21 percent over the same period 2020.
- Operating result amounted to -30.1 MSEK (-30.9)
- Net result after financial items amounted to -31.2 MSEK (-32.1)
- Earnings per share were -0,48 SEK (-0,58)
- Cash Balance amounted to 21.0 MSEK (14.8)
- Average Daily Treatment Revenue (ADTR)* was 146 TSEK (104), an increase of 40 percent over the same period in 2020.

Significant events during the period

- Dignitana AB announced in October that the CFO will leave the Company.

Business highlights during the period

- Dignitana announced sponsorship of the world's leading breast cancer organization, Susan G. Komen®, with DigniCap presence at three signature events in California and Florida.
- In July Dignitana signed distributor B&Co Group to support growth in Benelux.
- The Board of Directors has appointed The Chairman of the Board Klas Arildsson to the role of a working Chairman supporting growth from an operational point of view. He will focus on Quality and Regulatory Affairs and operational efficiency

Significant events after the period

- Dignitana announced a decision from Medicare enabling reimbursement to cancer centers providing DigniCap to chemotherapy patients in the US effective January 1, 2022.

Business highlights after the period

- Five DigniCap patients were recognized as DigniCap Dignitaries during Breast Cancer Awareness month and interviewed in weekly Facebook Live broadcasts in October.

"I firmly believe that we have made the right choices and realigned our organization to take the next step towards attaining our long-awaited goal of cash flow positivity."

William Cronin, CEO Dignitana AB



Key Figures

DIGNITANA GROUP	Q3 2021	Q3 2020	Q1-Q3 2021	Q1-Q3 2020	Full year 2020
Net sales, TSEK	13,657	10,884	40,860	33,701	46,629
Total revenues, TSEK	13,723	12,596	45,054	36,950	49,956
Net profit after financial items, TSEK	-13,916	-9,859	-31,240	-32,142	-52,963
Cash and bank balances, TSEK	21,047	14,796	21,047	14,796	78,770
Earnings per share before and after dilution, SEK	-0.21	-0.18	-0.48	-0.58	-0.96
Average Daily Treatment revenue*, TSEK	147	99	146	104	120

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

DIGNITANA AB IS A SWEDISH MEDICAL TECHNOLOGY COMPANY THAT PRODUCES AND MARKETS THE DIGNICAP SCALP COOLING SYSTEM TO MINIMIZE HAIR LOSS DURING CHEMOTHERAPY AND IMPROVE WELL-BEING AND QUALITY OF LIFE FOR CANCER PATIENTS.

Moving toward cash flow positivity in 2022 with accelerating reimbursement activity

The third quarter marked not just another positive step for the company but also one in which we were able to make significant strides strengthening our organization and investing in market access projects that we expect will pay large dividends for the company in the years to come. While the pandemic is still impacting the healthcare industry in general and the oncology market specifically, Dignitana continues to execute on our growth strategy and efforts to reach cash flow positivity.

We have continued to bring top tier new accounts online through both our direct sales efforts and our third-party distribution partners during a time where access to treatment centers remains limited and medical conferences are still primarily virtual. Internally, we have made significant investments in our quality systems and infrastructure and have allocated significant resources to our efforts to expand the scalp cooling market through insurance reimbursement. After the close of the period, in early November, we were extremely pleased to announce that the lengthy appeals process we initiated in June resulted in a significant increase in the reimbursable rate from Centers for Medicare and Medicaid Services (CMS) for health care providers offering scalp cooling to their patients.

This rate adjustment now enables providers to be properly compensated for the resources required to deliver this needed therapy. Prior to the initial assignment of the scalp cooling specific CPT codes and now an equitable reimbursement rate, health care providers had minimal incentive to apply valuable internal resources to this therapy as much as they may have wanted to.

Investment in Quality

As we have communicated previously, the company has made significant investments over the course of 2021 in improving our Quality System. A medical device company's Quality System is the lifeblood of the organization and ensures that it remains compliant with all international regulatory standards as well as offering the safest and most efficacious device possible. The investments we have made this year fulfill both of those needs and now enable the company to confidently enter more markets and act as the platform from which we can confidently leverage our market position as the clinically superior scalp cooling company.

Global Expansion

Global growth in the third period focused on India, an opportunity that the pandemic had previously placed on hold. Typical business operations there are resuming and several DigniCap Delta devices are now in India. Through our partnership with MedPhy Technologies, the market is already recognizing the competitive advantages that DigniCap Delta offers to chemotherapy providers and patients.

US Market

The company also invested significant financial resources in our Market Access efforts during the second and third quarters. These initiatives and investments are now beginning to pay off. In June CMS assigned a rate to scalp cooling that was far below a reasonable level. At that time Dignitana began an aggressive campaign to appeal that decision and obtain a much more equitable rate that would help many more patients to access this important therapy option. As noted earlier, that effort was successful after the close of the third period, with Medicare reimbursement now starting January 1, 2022. There is still work to do with both payors and providers, but there is no doubt that this extraordinary decision will help us to now reach our strategic goals much faster.

The US remains our primary marketplace and with the recent CMS rate decision we see an exceptional opportunity to grow with our existing customer base. As we have communicated previously, we have focused our efforts heavily on the community oncology practices that are offering cancer treatment services across a network of regional sites. We have only begun to tap the full potential of these partners in terms of both existing device utilization rates and broader systemic distribution. These particular community practices are extremely focused on finding ways to improve the economics of their infusion operations and now scalp cooling provides a unique way to do just that while also improving overall patient satisfaction.

Financial

As we focus our resources on improving device usage rates and work with our site partners to prepare for the January 1 start date for CMS reimbursement, I firmly believe that we have made the right choices and realigned our organization to take the next step towards attaining our long-awaited goal of cash flow positivity. Therefore, we anticipate attaining cash flow positivity in 2022. We maintain financing capacity under our long-term and improved lending facility. This can be tapped to fund additional unit placement as market adoption accelerates. The threefold combination of a solid business plan, a clearer reimbursement pathway, and most of the quality improvement and reimbursement costs behind us, enables us to confidently forecast positive financial performance.

Moving forward

I am tremendously excited at the potential for Dignitana's continued growth and the opportunity for The Company to reach critical milestones in 2022. In addition to cash flow positivity, our goals in the near term are to ensure all prospective customers are aware of DigniCap and our clinical superiority and also to ensure that every patient that wishes to use DigniCap has that opportunity. I firmly believe this will be a reality in the next 24 to 36 months and I am immensely appreciative of the support of our shareholders as we attain these goals together.



A handwritten signature in blue ink that reads "William Cronin".

William Cronin, CEO
Dignitana AB

The Company


DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors from breast cancer as well as those from prostate, ovarian, uterine, lung and other tissues. In 2019 Dignitana received CE Marking and FDA clearance for sales of DigniCap Delta, the next generation scalp cooling device, followed by approvals for the new model in Australia and Israel.

Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and operations are based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Redeye AB is Certified Adviser. The Company produces the DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse.

Business model

Dignitana has two business models: in the United States devices are leased and the Company receives payments for each treatment. Outside the U.S. devices are sold to facilities and the company also receives revenue from service and maintenance agreements. The introduction of the DigniCap Delta system has added an additional revenue stream from consumables to both models with sales of the single-patient DigniCap Delta caps and patient kits. The largest opportunity for growth is through the pay-per-treatment model as utilized in the United States.

For global markets that do not have the pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies. The new, single patient, DigniCap Delta is generating significant additional interest from the medical community, and we believe the trend towards greater infection control standards will generate additional momentum for the Company going forward.



The market

The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors. Globally there are over 12 million incidences of solid tumors diagnosed annually, with more than 1,8 million diagnoses occurring in the U.S. each year. Dignitana estimates that 60 percent of these patients are on regimens compatible with DigniCap. Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in women worldwide with over 1,7 million cases of breast cancer diagnosed annually. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers.

To increase awareness of scalp cooling we work strategically with different organizations and interest groups in the cancer care community. Dignitana's ongoing sponsorship of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this. In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this treatment vary widely, providing significant opportunities for Dignitana all over the world.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users. The Company has initiated several studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.

Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Scalp Cooling System has been marketed worldwide since 2009 and received FDA clearance for the US market in 2015. The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients. In 2019 DigniCap Delta received CE Marking for Europe and FDA clearance for the U.S., followed by TGA clearance for Australia.



Financial information and comments

DIGNITANA GROUP

Revenues

Group revenues are generated by direct sales of systems, leased systems, pay-per treatment fees, revenues from service and maintenance agreements, sales of individual caps and kit accessories. For the third quarter 2021 net sales amounted to 13 657 TSEK (10 884), an increase over the same period 2020 by 2 773 TSEK or 25 percent. YTD net sales reached 40 860 TSEK (33 701) and increase of 7 159 TSEK or 21 percent.

Dignitana operates by two business models: in the U.S. market DigniCap Delta systems are leased out and the Company gains revenues from leasing fees and payment for treatments. Outside the U.S, revenues are generated by DigniCap Delta systems being sold, frequently combined with service and maintenance agreements. In addition to this, the Company also has revenues from the sale of individual caps as well as consumables and accessories.

The U.S. market continues to be the driver in the transition to DigniCap Delta and a revised business model. During the quarter, 47 new DigniCap Delta units were installed, which yielded an installed base of 377 devices.

Dignitana's revenue and costs comprise of different currencies such as USD, EUR, and SEK. Operational exchange rate effects are recognized in the income statement either under other operating income or other operating expenses depending on the net effect. In the third quarter 2021 net exchange effects amounted to 875 TSEK (433) and YTD net exchange effects were 280 TSEK (-139). Exchange rate effects on financial holdings are recognized under other interest income and similar items and were for the third quarter -20 TSEK (250), YTD 4 TSEK (137).

Operating Expenses and Operating Result

Operating expenses increased during the quarter compared to the same period last year by 6 262 TSEK and amounted to -24 143 TSEK (-17 881) and YTD -65 740 TSEK (-56 062). The increase relates to expanding

business activities but is also the result of focused efforts to strengthen Quality and Regulatory Management within the Company, which together with reimbursement initiatives have generated non-recurring costs YTD September in the magnitude of 6.9 MSEK. Traveling and marketing costs are at moderate levels, while personnel costs have gone up given additional headcount.

Depreciation and amortization in the Group amounted to -3 173 TSEK (-4 173), YTD -9 451 TSEK (-11 857).

The operating result after depreciation for the Group amounted to -13 593 TSEK (-9 458) and decline over the same period 2020 of 4 135 TSEK. Operating loss YTD amounted to -30 137 TSEK (-30 969).

Financial net

Financial net was -323 TSEK (-401), with corresponding YTD numbers -1 103 TSEK (-1 173) and consists mainly of interest paid on loans.

Board and Management are continuously monitoring the financial position of the Company and are of the opinion that current business plans combined with unutilized credit facilities are sufficient financial resources to cover working capital needs for the coming 12-month period.

Employees

Number of employees is 28 (27) employees.

Cash Flow and Financial Position

Consolidated cash flows from operating activities during the quarter was -8 887 TSEK (-4 125), YTD -31 993 TSEK (-15 629). Cash and cash equivalents at the end of the quarter amounted to 21 047 TSEK (14 796).

CAPEX

Capex which amounted to 4 526 TSEK (5 365) in the quarter and YTD 9 433 TSEK (16 631), mainly relates to DigniCap Delta devices.

DIGNITANA PARENT COMPANY

Revenues

Total revenues the first quarter was 1 393 TSEK (9 092). Other income is attributable to exchange rate effects.

Operating Expenses and Operating Result

Operating expenses increased during the quarter compared to the same period last year by 1 534 TSEK and

amounted to -11 858 TSEK (-10 324).

Operating result was -13 580 TSEK (-5 339) and net result for the period was -19 857 TSEK (-16 674)

Revenue as well as expense variations between reporting periods are mainly related to timing differences of intercompany charges.

The share

Dignitana is listed on First North Growth Market since November 2011 after having been listed on Spotlight Market in Stockholm since June 2009.

Dignitana AB

TICKER	DIGN
Market Cap	528 MSEK
Number of shareholders, approximately	2 932
Share price September 30	8.12 SEK
Number of shares traded during the quarter	6 925 652
Number of shares outstanding September 30	65 059 155
Registered share capital	6 505 916 SEK
Par value	0,1 SEK
Certified Adviser	Redeye

Dignitana has only one category of shares, where each share carries one vote and equal rights to the Company's assets and profits. The Company has overtime issued new shares and stock option programs and in February 2020 an extraordinary general meeting was held where a decision was taken to issue a maximum of 2 500 000 employee warrants to key employees of the Company. The period for exercising the employee stock warrants will run from 1 March 2023 to 31 March 2023. The employee warrants were granted gratuitously and costs of 720 TSEK have been recognized in the third quarter closing, representing the YTD cost 2021.



In December 2020, the Board of Directors decided on a directed share issue of initially SEK 41,294,000 and an additional SEK 33 706 000 after approval by an Extraordinary General Meeting held in January 2021. Through the issue, which comprised 10 000 000 shares at a subscription price of SEK 7.50, the Company received 75 000 TSEK before issue costs.

Largest Shareholders

30 SEPTEMBER 2021	HOLDINGS	PERCENT
ADMA FÖRVALTNINGS AB	16 330 000	25.10%
SWEDBANK ROBUR MICROCAP	5 000 000	7.69%
FÖRSÄKRINGSAKTIEBOLAGET AVANZA PENSION	4 500 747	6.92%
CBLDN-UBS FINANCIAL SERVICES INC.	4 189 739	6.44%
HANDELSBANKEN MICROCAP SVERIGE	3 140 349	4.83%
FÖRSÄKRINGSAKTIEBOLAGET SKANDIA	2 708 888	4.16%
FE SMÅBOLAG SVERIGE	1 800 000	2.77%
TECHNOVOBIS AB	1 578 036	2.43%
POURSAMAD AMIR	1 520 095	2.34%
RÜLF, SEMMY	1 015 058	1.56%
TOTAL	41 782 912	64.24%
OTHER SHAREHOLDERS	23 276 243	35.76%
TOTAL	65 059 155	100.00%

Source: Euroclear



Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by several factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The non-definitive list of the Company's risks pertains, but is not limited, to: Patents, key personnel, growth management, management, restructuring, development costs, competitors, dependence on individual customers, customers, authorization and registration, chemotherapy without side effects, alternative cancer treatment methods, distributors and manufacturers, profitability and future capital requirements, political risk, pandemic risks, regulatory or change of laws, disputes and currency risks.

Risks related to COVID-19

The outbreak of COVID-19 in the spring of 2020 has affected the Company's opportunities to reach customers but also customers' ability to offer scalp cooling as a form of treatment. The Company has therefore been impacted financially, although it is not possible to make a full assessment.

The Board is ultimately responsible for managing and monitoring these risks. Ongoing management is delegated to the CEO, who in turn reports to the Board.

For a detailed explanation of these risk factors view the 2020 Annual Report posted at

<https://dignitana.com/investor-relations/financial-reports/>

Other information

Forward-looking statements

This report may contain statements, estimates or projections that constitute "forward-looking statements". Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Accounting principles

The consolidated financial statements comprise of Dignitana AB and its subsidiaries Dignitana Inc, and Dignitana Srl.

This interim report is prepared in accordance with Swedish GAAP, BFN 2012:1 (K3). The accounting policies remain unchanged compared with the preceding year and are the same principles that were applied for the Annual Report 2020.

Financial statements are presented in SEK, the functional currency of Dignitana AB. Assets and liabilities are translated and presented at the closing rate and the Income statement is translated and presented at period average exchange rates.

For a detailed explanation of accounting principles view the 2020 Annual Report posted at

<https://dignitana.com/investor-relations/financial-reports/>

This Interim Report has not been reviewed by the Group's Auditors.

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 18 November 2021

Dignitana AB (publ) Board of Directors

Klas Arildsson
Chairman of the Board

William Cronin
Board member and CEO

Richard Dilorio
Board member

Lina Karlsson
Board member

Christian Lindgren
Board member

Ljubo Mrnjavac
Board member

Income Statement – Dignitana Group, TSEK

DIGNITANA GROUP	Q3 2021	Q3 2020	Q1-Q3 2021	Q1-Q3 2020	Full year 2020
Operating Income					
Net sales	13 657	10 884	40 860	33 701	46 629
Other operating income	66	1 712	4 194	3 249	3 327
Total Operating Income	13 723	12 596	45 054	36 950	49 956
Operating expense					
Goods for Resale	-5 696	-4 116	-15 657	-9 692	-16 921
Operating expense	-5 440	-6 009	-21 818	-23 311	-29 870
Personnel expense	-7 734	-5 824	-22 285	-19 277	-28 280
Depreciation and amortization of tangible and intangible assets	-3 173	-4 173	-9 451	-11 857	-20 764
Other operating expenses	-5 273	-1 932	-5 980	-3 782	-4 822
	-27 316	-22 054	-75 191	-67 919	-100 656
Operating profit (loss)	-13 593	-9 458	-30 137	-30 969	-50 700
Result from financial investments					
Other Interest income and similar items	14	107	93	139	1
Interest expenses and similar items	-337	-508	-1 196	-1 312	-2 264
	-323	-401	-1 103	-1 173	-2 263
Profit after financial items	-13 916	-9 859	-31 240	-32 142	-52 963
Profit before tax	-13 916	-9 859	-31 240	-32 142	-52 963
Tax on profit for the period	0	0	0	0	0
Results for the Period	-13 916	-9 859	-31 240	-32 142	-52 963
Average number of shares before and after dilution	65 059 155	55 059 155	65 059 155	55 059 155	60 565 070
Earnings per share before and after dilution, SEK	-0,21	-0,18	-0,48	-0,58	-0,96

Balance Sheet – Dignitana Group, TSEK

DIGNITANA GROUP	2021-09-30 2021	2020-09-30 2020	2020-12-31 2020
ASSETS			
FIXED ASSETS			
Intangible assets			
Capitalized expenses for development	12 421	18 016	16 233
	12 421	18 016	16 233
Tangible assets			
Equipment, tools and installations	31 313	30 884	27 501
	31 313	30 884	27 501
Total Fixed Assets	43 734	48 900	43 734
CURRENT ASSETS			
Inventories and similar			
Finished goods and goods for resale	7 741	10 362	7 455
	7 741	10 362	7 455
Current Receivables			
Accounts Receivable	5 711	4 498	5 435
Current Tax Assets	102	9	61
Other Current Receivables	933	1 381	1 071
Prepaid expenses and accrued income	1 355	992	1 363
	8 101	6 880	7 930
Cash and Bank Balances	21 047	14 796	78 770
Total Current Assets	36 889	32 038	94 155
Total Assets	80 623	80 938	137 889
EQUITY AND LIABILITIES			
Equity			
Share Capital	6 506	55 059	6 057
Unregistered share capital	0	0	449
Ongoing new issue	0	0	33 256
Other contributed capital	222 692	153 474	189 436
Other equity including profit for the year	-184 801	-184 041	-151 562
Total Equity	44 397	24 492	77 636
Provisions			
Other provisions	18	0	18
	18	0	18
Long Term Liabilities			
Other long term liabilities	11 014	3 610	1 661
Total Long Term Liabilities	11 014	3 610	1 661
Current Liabilities			
Liabilities to credit institutions	4 708	9 486	7 968
Accounts payable	10 518	11 833	13 327
Other current liabilities	870	23 981	23 737
Accrued expenses and deferred income	9 098	7 536	13 541
Total current liabilities	25 194	52 836	58 573
Total liabilities	36 208	56 446	60 235
Total Equity and Liabilities	80 623	80 938	137 889

Changes in Equity – Dignitana Group, TSEK

	Sharecapital	Other contributed capital	Retained earnings, incl. net loss for the year	Total equity
Opening equity on 1/1/2020	55 059	153 067	-153 023	55 103
New share issue	551	40 744		41 294
Ongoing new share issue	449	33 256		33 706
Reduction of share capital	-49 553		49 553	0
Issue expenses		-4 564		-4 564
Issue of warrants		189		189
Option program 2020			960	960
Net loss for the year			-52 963	-52 963
Change in translation difference relating to subsidiaries			3 912	3 912
Closing equity on 12/31/2020	6 506	222 692	-151 562	77 636
Net loss for the period			-31 240	-31 240
Option program 2021			720	720
Change in translation difference relating to subsidiaries			-2 719	-2 719
Closing equity on 09/30/2021	6 506	222 692	-184 801	44 397

Statement of Cash Flows – Dignitana Group, TSEK

DIGNITANA GROUP	Q3 2021	Q3 2020	Q1-Q3 2021	Q1-Q3 2020	Full year 2020
Operating activities					
Profit after financial investments	-13 915	-9 859	-31 240	-32 142	-52 963
Adjustments for items not affecting cash flows, etc	3 584	4 846	7 564	12 529	26 789
Tax paid	-15	12	-105	305	253
Cash flow from operating activities before changes in working capital	-10 346	-5 001	-23 781	-19 308	-25 921
Cash flow from changes in working capital					
Change in inventories	-960	-838	-251	-1 019	-1 509
Change in other current receivables	589	812	413	3	-1 214
Change in other current liabilities	1 830	902	-8 374	4 695	7 341
Cash flows from operating activities	-8 887	-4 125	-31 993	-15 629	-21 303
Investing activities					
Investments in intangible assets	0	-569	0	-722	-739
Proceeds from sale of intangible assets	0	0	0	0	0
Investments in tangible assets	-4 526	-4 796	-9 433	-15 909	-19 665
Cash flows from investing activities	-4 526	-5 365	-9 433	-16 631	-20 404
Financing activities					
New share issue	0	0	0	0	75 000
Issue expenses	0	0	0	218	-170
Liabilities to credit institutions	0	0	0	189	189
Options issued	0	0	0	0	0
New loans	0	20 000	0	20 000	20 000
Repaid loans	0	0	-20 000	0	0
Change in short and long term liabilities	-1 026	-3 145	5 201	6 203	3 487
Cash flow from financial activities	-1 026	16 855	-14 799	26 610	98 506
Cash flow for the period	-14 439	7 365	-56 225	-5 650	56 799
Cash and cash equivalents at beginning of period					
Cash and cash equivalents at beginning of period	36 333	7 483	78 770	19 433	19 433
Exchange-rate differences in cash and cash equivalents					
Exchange-rate differences in cash and cash equivalents	-847	-52	-1 498	1 013	2 538
Cash and cash equivalents at end of period	21 047	14 796	21 047	14 796	78 770

Income Statement – Dignitana AB, Parent Company, TSEK

DIGNITANA GROUP	Q3 2021	Q3 2020	Q1-Q3 2021	Q1-Q3 2020	Full year 2020
Operating Income					
Net sales	1 393	7 416	20 053	22 762	31 324
Other operating income	0	1 676	988	3 382	3 448
Total Operating Income	1 393	9 092	21 041	26 144	34 772
Operating expense					
Goods for Resale	-2 243	-2 579	-6 655	-5 578	-10 257
Operating expense	-5 537	-5 511	-12 651	-20 503	-26 372
Personnel expense	-2 984	-477	-10 620	-1 496	-2 301
Depreciation and amortization of tangible and intangible assets	-3 115	-4 107	-9 283	-11 642	-20 483
Other operating expenses	-1 094	-1 757	-1 689	-3 599	-4 510
	-14 973	-14 431	-40 898	-42 818	-63 923
Operating profit (loss)	-13 580	-5 339	-19 857	-16 674	-29 152
Result from financial investments					
Other Interest income and similar items	15	138	94	138	0
Interest expenses and similar items	-35	-134	-459	-256	-918
	-20	4	-365	-118	-918
Profit after financial items	-13 600	-5 335	-20 222	-16 792	-30 069
Profit before tax	-13 600	-5 335	-20 222	-16 792	-30 069
Tax on profit for the period	0	0	0	0	0
Results for the Period	-13 600	-5 335	-20 222	-16 792	-30 069

Balance Sheet – Dignitana AB, Parent Company, TSEK

DIGNITANA AB, PARENT COMPANY	2021-09-30 2021	2020-09-30 2020	2020-12-31 2020
ASSETS			
FIXED ASSETS			
Intangible assets			
Capitalized expenses for development	12 396	17 987	16 207
	12 396	17 987	16 207
Tangible assets			
Equipment, tools and installations	31 101	30 545	27 223
	31 101	30 545	27 223
Financial assets			
Participations in group companies	522	522	522
Receivable from group companies	440	449	409
	962	971	931
Total Fixed Assets	44 459	49 503	44 361
CURRENT ASSETS			
Inventories and similar			
Finished goods and goods for resale	5 026	9 131	6 143
	5 026	9 131	6 143
Current Receivables			
Accounts Receivable	1 366	1 136	1 775
Receivables from group companies	30 276	13 441	18 207
Current Tax Assets	102	9	61
Other Current Receivables	836	1 139	911
Prepaid expenses and accrued income	483	414	536
	33 063	16 139	21 490
Cash and Bank Balances	16 014	11 075	76 505
Total Current Assets	54 103	36 345	104 138
Total Assets	98 562	85 848	148 499
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share Capital	6 506	55 059	6 057
Unregistered share capital	0	0	449
Fund for development expenses	12 281	16 719	15 631
	18 787	71 778	22 137
Non-restricted equity			
Share premium reserves	222 692	153 475	222 692
Other non-restricted equity	-130 559	-154 480	-103 839
Results for the period	-20 222	-16 792	-30 069
	71 911	-17 797	88 784
Total Equity	90 698	53 981	110 921
Current Liabilities			
Accounts payable	3 247	8 321	8 620
Current payable to group company	0	0	0
Other current liabilities	130	20 134	20 120
Accrued expenses and deferred income	4 487	3 412	8 838
Total current liabilities	7 864	31 867	37 578
Total liabilities	7 864	31 867	37 578
Total Equity and Liabilities	98 562	85 848	148 499

Financial calendar

17 February 2022	2021 Year End Report
19 May 2022	Q1 Report
19 May 2022	Annual General Meeting
18 August 2022	Q2 Report
17 November 2022	Q3 report
16 February 2023	2022 Year End Report

All financial reports are available at

www.dignitana.com/investor-relations/financial-reports/

Contact information

Dignitana AB

Traktorgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
info@dignitana.com
investorrelations@dignitana.com
www.dignitana.se

Certified Adviser

Redeye AB
+46 8 121 576 90
certifiedadviser@redeye.se
www.redeye.se